22OCT

Arrakis: Blossom's second lead in 3 days

1 min read

16:30UTC

Arrakis, a London AI company, raised £22.5m on 24 July led by Blossom Capital, three days after the same fund led a twenty-one-year-old propulsion firm.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Arrakis closed £22.5m without a public product, which at Series A scale is now unremarkable.

Arrakis, a London artificial-intelligence (AI) company, raised a £22.5 million Series A on Friday 24 July led by Blossom Capital, with the venture funds Accel, GFC, MainObject and Rerail following⁠¹.

That is Blossom's second Series A lead in three days. On the Tuesday it led a Bedford propulsion company with patents, aircraft customers and twenty-one years of trading behind it. On the Friday it led an AI company at seed-plus scale. One fund, two leads, opposite ends of the evidence spectrum.

The weekly roundup labels Arrakis an AI company and names no product or market, and we could not reach a company release⁠². That absence is itself ordinary now. AI companies took a record share of UK smaller-business equity value last year, and at Series A scale a round can close on a founding team and a thesis before anything ships. We report the cheque and the syndicate, and leave the rest until somebody publishes it.

Deep Analysis

In plain English

Arrakis is a London company working on artificial intelligence software. It raised £22.5m from investors including Accel and GFC, with Blossom Capital leading the round. This was Blossom's second time leading a funding round in just three days, having also led Bedford company Greenjets' £30m raise days earlier, showing the same investment fund actively writing large cheques into very different kinds of British technology companies in the same week.

Deep Analysis

Root Causes

A single fund leading two Series A rounds three days apart reflects how venture partnerships allocate capital, not a hot sector. Partners at a fund like Blossom Capital run independent deal pipelines.

Two unrelated leads landing in the same week reflects diary timing and due-diligence completion dates rather than a coordinated thesis linking Greenjets' electric propulsion to Arrakis' AI software.

What could happen next?

Meaning
Blossom Capital's back-to-back leads signal an active deployment pace at the fund rather than a thematic bet spanning propulsion hardware and AI software.

Sources:UKTN

Mentions:NATO Innovation Fund →Kraken Technology Group →Arrakis →BOKA Capital →Accel →GFC →MainObject →Rerail →London →Greenjets →Blossom Capital →

First Reported In

Update #13 · Humanoid hit $1.35bn on a customer order

UKTN· 31 Jul 2026

Read original →

Causes and effects

Caused by

Greenjets raises £30m in its 21st year

Blossom Capital's lead in Arrakis followed its Greenjets lead three days earlier, the same fund backing opposite ends of the evidence spectrum.

Occurred 21 Jul 2026

Read story →

This Event

Arrakis: Blossom's second lead in 3 days

One fund led two Series A rounds in the same week at opposite ends of the evidence spectrum, and the AI company's product remains unnamed in public.

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.